{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hepatocellular+Carcinoma+%28Hepatoma%29&page=28",
    "query": {
      "condition": "Hepatocellular Carcinoma (Hepatoma)",
      "page": 28
    },
    "page_size": 10
  },
  "pagination": {
    "page": 28,
    "page_size": 10,
    "total_count": 1037,
    "total_pages": 104,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hepatocellular+Carcinoma+%28Hepatoma%29&page=29&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hepatocellular+Carcinoma+%28Hepatoma%29&page=27&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-02T00:33:55.016Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05233098",
      "title": "TheraSphere Post-Approval Study to Calculate the Radiation-absorbed Dose of Tc-99m MAA.",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "Technetium-99m macroaggregated albumin (Tc-99m MAA)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Boston Scientific Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2022-04-04",
      "completion_date": "2023-06-14",
      "has_results": true,
      "last_update_posted_date": "2025-03-06",
      "last_synced_at": "2026-11-02T00:33:55.016Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05233098"
    },
    {
      "nct_id": "NCT00539643",
      "title": "Trial of Beads Versus Doxorubicin Eluting Beads for Arterial Embolization of Hepatocellular Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatocellular Carcinoma",
        "Liver Cancer",
        "Hepatoma"
      ],
      "interventions": [
        {
          "name": "Bead Block microspheres",
          "type": "DEVICE"
        },
        {
          "name": "Bead + Dox Arm",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 101,
      "start_date": "2007-11",
      "completion_date": "2022-06-17",
      "has_results": true,
      "last_update_posted_date": "2023-08-18",
      "last_synced_at": "2026-11-02T00:33:55.016Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00539643"
    },
    {
      "nct_id": "NCT03695250",
      "title": "BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Hepatocellular Carcinoma",
        "Stage III Hepatocellular Carcinoma AJCC v8",
        "Stage IIIA Hepatocellular Carcinoma AJCC v8",
        "Stage IIIB Hepatocellular Carcinoma AJCC v8",
        "Stage IV Hepatocellular Carcinoma AJCC v8",
        "Stage IVA Hepatocellular Carcinoma AJCC v8",
        "Stage IVB Hepatocellular Carcinoma AJCC v8",
        "Unresectable Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "IDO1 Inhibitor BMS-986205",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Edward Kim",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2018-10-16",
      "completion_date": "2021-03-12",
      "has_results": true,
      "last_update_posted_date": "2026-07-29",
      "last_synced_at": "2026-11-02T00:33:55.016Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03695250"
    },
    {
      "nct_id": "NCT02562755",
      "title": "Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatocellular Carcinoma (HCC)"
      ],
      "interventions": [
        {
          "name": "Pexastimogene Devacirepvec (Pexa Vec)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "SillaJen, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 459,
      "start_date": "2015-10",
      "completion_date": "2020-07",
      "has_results": true,
      "last_update_posted_date": "2026-06-08",
      "last_synced_at": "2026-11-02T00:33:55.016Z",
      "location_count": 23,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Orange, California + 19 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02562755"
    },
    {
      "nct_id": "NCT06084884",
      "title": "A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "AZD5851",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 94,
      "start_date": "2023-12-14",
      "completion_date": "2027-12-13",
      "has_results": false,
      "last_update_posted_date": "2026-08-19",
      "last_synced_at": "2026-11-02T00:33:55.016Z",
      "location_count": 16,
      "location_summary": "Phoenix, Arizona • Duarte, California • Los Angeles, California + 13 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06084884"
    },
    {
      "nct_id": "NCT00004248",
      "title": "Doxorubicin and Interleukin-2 in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Liver Cancer"
      ],
      "interventions": [
        {
          "name": "aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "doxorubicin hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "1999-07",
      "completion_date": "2001-05",
      "has_results": false,
      "last_update_posted_date": "2011-03-07",
      "last_synced_at": "2026-11-02T00:33:55.016Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004248"
    },
    {
      "nct_id": "NCT01896778",
      "title": "Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Adult Liver Carcinoma",
        "Breast Carcinoma",
        "Colon Carcinoma",
        "Kidney Neoplasm",
        "Lung Carcinoma",
        "Malignant Head and Neck Neoplasm",
        "Malignant Neoplasm",
        "Melanoma",
        "Ovarian Neoplasm",
        "Soft Tissue Sarcoma"
      ],
      "interventions": [
        {
          "name": "Hyperthermia Treatment",
          "type": "PROCEDURE"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2013-10-04",
      "completion_date": "2018-02-23",
      "has_results": false,
      "last_update_posted_date": "2022-07-25",
      "last_synced_at": "2026-11-02T00:33:55.016Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01896778"
    },
    {
      "nct_id": "NCT00310115",
      "title": "Motivational Counseling in Preventing Smoking Relapse After Pregnancy in Pregnant Women Who Quit Smoking During Pregnancy",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Bladder Cancer",
        "Cervical Cancer",
        "Esophageal Cancer",
        "Gastric Cancer",
        "Head and Neck Cancer",
        "Kidney Cancer",
        "Leukemia",
        "Liver Cancer",
        "Lung Cancer",
        "Pancreatic Cancer",
        "Tobacco Use Disorder"
      ],
      "interventions": [
        {
          "name": "Smoking Prevention Usual Care",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Counseling Intervention",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 469,
      "start_date": "2002-04",
      "completion_date": "2016-08",
      "has_results": false,
      "last_update_posted_date": "2016-09-23",
      "last_synced_at": "2026-11-02T00:33:55.016Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00310115"
    },
    {
      "nct_id": "NCT01258608",
      "title": "Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Hepatocellular"
      ],
      "interventions": [
        {
          "name": "Mapatumumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Sorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Human Genome Sciences Inc., a GSK Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 101,
      "start_date": "2011-02-08",
      "completion_date": "2017-11-29",
      "has_results": true,
      "last_update_posted_date": "2018-12-19",
      "last_synced_at": "2026-11-02T00:33:55.016Z",
      "location_count": 9,
      "location_summary": "Aurora, Colorado • Shreveport, Louisiana • Rochester, Minnesota + 5 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Tupelo",
          "state": "Mississippi"
        },
        {
          "city": "Newark",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01258608"
    },
    {
      "nct_id": "NCT01631552",
      "title": "Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Gastric Adenocarcinoma",
        "Esophageal Cancer",
        "Hepatocellular Carcinoma",
        "Non-small Cell Lung Cancer",
        "Small Cell Lung Cancer",
        "Ovarian Epithelial Cancer",
        "Carcinoma Breast Stage IV",
        "Hormone-refractory Prostate Cancer",
        "Head and Neck Cancers- Squamous Cell",
        "Renal Cell Cancer",
        "Urinary Bladder Neoplasms",
        "Cervical Cancer",
        "Endometrial Cancer",
        "Glioblastoma Multiforme",
        "Triple Negative Breast Cancer",
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Sacituzumab Govitecan-hziy (SG)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 515,
      "start_date": "2012-12-17",
      "completion_date": "2020-08-13",
      "has_results": true,
      "last_update_posted_date": "2021-08-12",
      "last_synced_at": "2026-11-02T00:33:55.016Z",
      "location_count": 12,
      "location_summary": "Aurora, Colorado • New Haven, Connecticut • Newark, Delaware + 8 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01631552"
    }
  ]
}